v3.26.1
Segment Information - Summary of Reconciliation of Reported Operating Expenses to Net Loss Under the Significant Expenses Principle (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Research and development:            
Indirect expenses $ 2,059   $ 1,840   $ 3,950 $ 3,853
Personnel-related expenses 6,067   6,469   12,905 13,920
Total research and development expenses 13,812   21,151   29,410 40,586
Selling, general and administrative 5,284   4,928   10,506 10,252
Total operating expenses 19,096   26,079   39,916 50,838
Other income (expense), net (6,442)   (1,810)   23,596 (786)
Net loss and comprehensive loss (25,538) $ 9,218 (27,889) $ (23,735) (16,320) (51,624)
Revita Direct Program Expenses            
Research and development:            
Total research and development expenses 3,676   8,181   8,642 14,935
Rejuva Direct Program Expenses            
Research and development:            
Total research and development expenses $ 2,010   $ 4,661   $ 3,913 $ 7,878